Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells

2019 ◽  
Vol 516 (3) ◽  
pp. 693-698 ◽  
Author(s):  
Naoya Yamashita ◽  
Yuichiro Kanno ◽  
Nao Saito ◽  
Kensuke Terai ◽  
Noriko Sanada ◽  
...  
2021 ◽  
Vol 22 (4) ◽  
pp. 1654
Author(s):  
Jinyun Chen ◽  
Yujie Yang ◽  
Wade A. Russu ◽  
William K. Chan

The aryl hydrocarbon receptor (AHR) is a ligand-activated signaling molecule expressed in many cell types, including triple-negative and non-triple-negative breast cancer cells. It affects breast cancer growth and crosstalk with estrogen receptor signaling. Normally, this receptor is degraded shortly after ligand activation via the 26S proteasome. Here, we report that AHR undergoes chaperone-mediated autophagy in MDA-MB-468 triple-negative breast cancer cells. This lysosomal degradation of AHR exhibits the following characteristics: (1) it is triggered by 6 amino-nicotinamide, starvation, and piperazinylpyrimidine compound Q18; (2) it is not observed in non-triple-negative breast cancer cells (MCF-7, T47D, and MDA-MB-361); (3) it can be inhibited by progesterone receptor B but not estrogen receptor alpha; (4) it can be reversed by chloroquine but not MG132; (5) it requires LAMP2A; and (6) it involves AHR-HSC70 and AHR-LAMP2A interactions. The NEKFF sequence localized at amino acid 558 of human AHR appears to be a KFERQ-like motif of chaperone-mediated autophagy, responsible for the LAMP2A-mediated AHR protein degradation.


2017 ◽  
Vol 12 (1) ◽  
pp. 221-229
Author(s):  
Abeer M. Ashmawy ◽  
Mona A. Sheta ◽  
Faten Zahran ◽  
Abdel Hady A. Abdel Wahab

2021 ◽  
Vol 17 (4) ◽  
pp. 513-522
Author(s):  
Xuye Zhao ◽  
Xiangdong Bai ◽  
Weina Li ◽  
Xuezhen Gao ◽  
Xiaoli Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document